Nautilus Biotechnolgy, Inc.

Nautilus Biotechnolgy, Inc.

NAUT
Nautilus Biotechnolgy, Inc.US flagNASDAQ Capital Market
0.90
USD
-0.01
- -
115.15MMarket Cap
Nautilus Biotechnolgy, Inc.
NAUT
(NASDAQ Capital Market)

Recent

price

0.90

P/E

ratio

- -

div

yld

- -

ROIC.AI

2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-0.13
-0.6
-0.46
-0.51
-0.56
-0.47
-0.45
Basic EPS, GAAP
-0.12
-0.49
-0.39
-0.43
-0.49
-0.41
-0.41
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.24
2.92
2.52
2.12
1.66
1.24
1.03
Book Value per Share
-0.24
2.92
2.52
2.12
1.66
1.24
1.03
Tangible Book Value per Share
124
84
125
125
125
126
127
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
-627,830
Operating Margin (%)
2
3
3
6
6
6
6
Depreciation Expense
-16
-50
-58
-64
-71
-59
-57
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
-565,210
Profit Margin (%)
75
343
180
168
125
98
79
Working Capital
3
29
28
31
26
26
24
LT Debt
-30
364
315
265
209
157
131
Total Equity
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
-17.07
-21.95
-29.86
-32.27
-36.21
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
4
4
4
LT Borrowings
- -
- -
- -
LT Finance Leases
26
25
24
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
126
127
127
Market Capitalization
247
493
238

Working Capital

FRC

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
106
99
88
Cash, Cash Equivalents & STI
103
96
84
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
8
8
9
Payables & Accruals
1
2
2
ST Debt
4
4
4
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-279.71%
-24.8%
Free Cash Flow
- -
40.94%
-15.17%
Net Income, GAAP
- -
48.34%
-16.64%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.15
-0.14
-0.13
-0.14
-0.56
2025
-0.13
-0.12
-0.11
-0.11
-0.47
2026
-0.12
-0.11
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Nautilus Biotechnology, Inc. is a life sciences firm focused on developing a groundbreaking platform for comprehensive proteome analysis. This innovative company is actively creating the Nautilus Platform, a complete solution designed for single-molecule protein detection, encompassing sophisticated instruments, specialized consumables, and advanced software for data interpretation. Established in 2016 and based in Seattle, Washington, the enterprise is set to revolutionize biological discovery and drug development by providing unprecedented depth and precision in understanding protein function. The company's unique technology aims to reveal low-abundance proteins and their precise modifications, advancing beyond the capabilities of conventional methods. Recently, Nautilus reported the successful deployment and evaluation of its initial field unit at the Buck Institute for Research on Aging and continues to prepare for its anticipated commercial launch in 2026.

Company News

  • Nature Methods Publication Reveals Deep Insights into Functional Biology through First-of-its-Kind Quantification of Tau Proteoforms

  • Nautilus Biotechnology: Contrarian Proteoformics Play After The Recent Pullback

  • Nautilus Biotechnology, Inc. (NAUT) Q2 2026 Earnings Call Transcript

  • Nautilus Biotechnology Q2 Earnings Call Highlights

  • Nautilus Biotechnology Reports Second Quarter 2026 Financial Results

  • Nautilus Biotechnology to Announce Second Quarter 2026 Financial Results on July 28, 2026

  • 3 Small-Cap Stocks to Buy Before May 15

  • Nautilus Biotechnology, Inc. (NAUT) Q1 2026 Earnings Call Transcript

  • Nautilus Biotechnology Reports First Quarter 2026 Financial Results

  • Forget Neuralink: The Real Brain Tech Trade Has 10 Names You’ve Never Heard

  • Nautilus Biotechnology Announces Baylor College of Medicine as First Early Access Program Customer for Voyager Platform

  • Nautilus Biotechnology, Inc. (NAUT) Presents at TD Cowen 46th Annual Health Care Conference Transcript

  • Nautilus Biotechnology, Inc. (NAUT) Q4 2025 Earnings Call Transcript

  • Nautilus Biotechnology to Participate in the TD Cowen 46th Annual Health Care Conference

  • Nautilus Biotechnology Reports Successful Installation and Testing of its First Field Evaluation Unit at the Buck Institute for Research on Aging

  • Nautilus Biotechnology, Inc. (NAUT) Q3 2025 Earnings Call Transcript

  • Nautilus Biotechnology, Inc. (NAUT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

  • Nautilus Biotechnology, Inc. (NAUT) Q2 2025 Earnings Conference Call Transcript

  • Nautilus Biotechnology Reports Second Quarter 2025 Financial Results

  • Nautilus Biotechnology to Announce Second Quarter 2025 Financial Results on July 31, 2025